CTOs on the Move

Detroit Wayne Mental Health Authority

www.dwihn.org

 
DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.dwihn.org
  • 707, West Milwaukee Avenue
    Detroit, MI USA 48202
  • Phone: 313.344.9099

Executives

Name Title Contact Details

Similar Companies

First Boston Pharma

First Boston Pharma, LLC is a Gloucester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kyorin USA

Kyorin USA is a Teaneck, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GlaxoSmithKline

We are a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. As one of the few healthcare companies researching both medicines and vaccines for the World Health Organization`s three priority diseases – HIV/AIDS, tuberculosis and malaria, we are very proud to have developed some of the leading global medicines in these fields. Our product portfolio also includes a range of consumer brands, many of which are household names around the world, including Sensodyne, Aquafresh, Horlicks, Panadol and Tums.

Stason Pharmaceuticals Inc

Stason Pharmaceuticals Inc is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.